GH (NASDAQ) - Guardant Health | Stock Price & Analysis

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40131M1099
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for GH (NASDAQ) - Guardant Health | Stock Price & Analysis


Market Cap in USD 2,747m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Health Care Services
TER 0.00%
IPO / Inception 2018-10-04


Fundamental -5.74
Dividend -
Performance 5y -2.82
Rel. Performance vs Sector -2.49
Analysts 4.68
Fair Price Total Ret. 21.96
Fair Price DCF todo


Growth TTM -51.97%
CAGR 5y -11.32%
CAGR / Mean Drawdown -0.26
Sharpe Ratio TTM -0.90
Alpha vs SP500 TTM -69.68
Beta vs SP500 5y weekly 1.45
CAPM 9.27%
Average Daily Range 2m 5.48%
Reversal Oscillator 69.14
Volatility GJR Garch 1y 76.55%
Price / SMA 50 -3.16%
Price / SMA 200 -15.73%
Current Volume 1448.9k
Average Volume 20d 1892.4k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%